{"id":"savella","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":["WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS SAVELLA is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some drugs used for the treatment of depression and other psychiatric disorders. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of such drugs in a c"],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01488266","NCT00098124","NCT06786481","NCT02265367","NCT00757731","NCT01014585","NCT06804577","NCT06591091","NCT00618956","NCT03569475","NCT01254305","NCT01337700","NCT01125423","NCT01510457","NCT02288325","NCT01108731","NCT01288937","NCT01289236","NCT05737511","NCT01777581","NCT05384210","NCT01026077","NCT00757679","NCT01319825","NCT01418651","NCT00793520","NCT07253207","NCT01329406","NCT02466958","NCT01207453","NCT01780389","NCT01225068","NCT00436033","NCT01829243","NCT03249311","NCT01377194","NCT03905486","NCT00817375","NCT01173055","NCT02783430","NCT00969150","NCT01085812","NCT01288807","NCT03128021","NCT01471379","NCT03797560","NCT01352572","NCT00314249","NCT00969709","NCT03321526"],"aliases":["HCL (Savella), Milnacipran"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Savella","companyId":"brigham-and-women-s-hospital","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Brigham and Women's Hospital","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Savella","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01488266","phase":"NA","title":"Comparison of Aripiprazole Augmentation vs Switching to Different Class of Antidepressants for Patients With MDD Who Are Partially/Minimally Responsive to Current Antidepressants:Randomized, Rater-bli","status":"UNKNOWN","sponsor":"Korea University","isPivotal":false,"enrollment":90,"indication":"Major Depressive Disorder","completionDate":"2013-03"},{"nctId":"NCT00098124","phase":"Phase 3","title":"A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for the Treatment of Fibromyalgia","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":1200,"indication":"Fibromyalgia","completionDate":"2006-12"},{"nctId":"NCT06786481","phase":"NA","title":"Effect of Foot Massage Performed to the Mother After Post-Bırth on Breastfeedıng Success, Sleep Qualıty and Neonatal Stress: a Randomızed Controlled Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melek Nur KEÇELİ","isPivotal":false,"enrollment":70,"indication":"Postpartum Women","completionDate":"2025-08-30"},{"nctId":"NCT02265367","phase":"NA","title":"Novel Medication as a Potential Smoking Cessation Aid","status":"COMPLETED","sponsor":"University of Minnesota","isPivotal":false,"enrollment":56,"indication":"Tobacco Use Disorder","completionDate":"2017-05"},{"nctId":"NCT00757731","phase":"Phase 3","title":"A European Phase III, Multicentre, Double-blind, Randomised, Monotherapy, 12-month Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","isPivotal":true,"enrollment":490,"indication":"Fibromyalgia Syndrome","completionDate":"2008-10"},{"nctId":"NCT01014585","phase":"Phase 4","title":"A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipr","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":false,"enrollment":340,"indication":"Fibromyalgia","completionDate":""},{"nctId":"NCT06804577","phase":"NA","title":"Effect of Peanut Ball Use ın Prımarıes on Labor Paın, Duratıon of Labor Anxıety and Maternal Satısfactıon","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ayşe FİLİZ","isPivotal":false,"enrollment":108,"indication":"First Birth, Labor Pain","completionDate":"2025-11-30"},{"nctId":"NCT06591091","phase":"Phase 2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","isPivotal":false,"enrollment":80,"indication":"Depression","completionDate":"2026-03"},{"nctId":"NCT00618956","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Milnacipran 100 And 200 MG Daily in Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":321,"indication":"Fibromyalgia","completionDate":""},{"nctId":"NCT03569475","phase":"Phase 3","title":"A Double-blind, Placebo- and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder","status":"COMPLETED","sponsor":"Allergan","isPivotal":true,"enrollment":501,"indication":"Major Depressive Disorder","completionDate":"2021-03-01"},{"nctId":"NCT01254305","phase":"Phase 2","title":"A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":false,"enrollment":262,"indication":"Major Depressive Disorder","completionDate":"2012-07"},{"nctId":"NCT01337700","phase":"Phase 4","title":"Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism","status":"COMPLETED","sponsor":"Montefiore Medical Center","isPivotal":false,"enrollment":10,"indication":"Autism Spectrum Disorder, Asperger Syndrome","completionDate":"2014-07"},{"nctId":"NCT01125423","phase":"Phase 4","title":"An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Milnacipran","status":"COMPLETED","sponsor":"Albany Medical College","isPivotal":false,"enrollment":27,"indication":"Fibromyalgia","completionDate":"2013-01"},{"nctId":"NCT01510457","phase":"Phase 4","title":"Milnacipran for the Pain, Sensory Sensitization and Mood Changes in Knee Osteoarthritis","status":"COMPLETED","sponsor":"Dr. Norman Harden","isPivotal":false,"enrollment":46,"indication":"Knee Osteoarthritis, Degenerative Joint Disease","completionDate":"2013-10"},{"nctId":"NCT02288325","phase":"Phase 4","title":"A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":false,"enrollment":644,"indication":"Depressive Disorder, Major","completionDate":"2016-09-16"},{"nctId":"NCT01108731","phase":"Phase 2","title":"The Effect of Milnacipran or Placebo on Ventricular Lactate Levels and Fibromyalgia Induced \"Brain Fog.\"","status":"COMPLETED","sponsor":"Beth Israel Medical Center","isPivotal":true,"enrollment":37,"indication":"Fibromyalgia","completionDate":"2014-01"},{"nctId":"NCT01288937","phase":"Phase 3","title":"A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain","status":"TERMINATED","sponsor":"Columbia University","isPivotal":true,"enrollment":6,"indication":"Idiopathic Peripheral Neuropathy","completionDate":"2014-12-23"},{"nctId":"NCT01289236","phase":"Phase 4","title":"An Exploratory, Randomized, Single Blinded, Placebo-Controlled, Dose-Ranging Study of the Safety and Efficacy of \"MILNACIPRAN\" in Subjects With Chronic Shoulder Pain","status":"COMPLETED","sponsor":"Valera Bussell","isPivotal":false,"enrollment":40,"indication":"Chronic Shoulder Pain","completionDate":"2011-06"},{"nctId":"NCT05737511","phase":"Phase 4","title":"Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial.","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","isPivotal":false,"enrollment":80,"indication":"Panic Disorder","completionDate":"2026-12-30"},{"nctId":"NCT01777581","phase":"Phase 4","title":"A Ten-Week, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Milnacipran for Radicular Pain Associated With Lumbosacral Disk Disease","status":"COMPLETED","sponsor":"Duke University","isPivotal":false,"enrollment":13,"indication":"Radicular Pain Related to Lumbosacral Disc Disease","completionDate":"2011-10"},{"nctId":"NCT05384210","phase":"NA","title":"Effect of Milnacipran Versus Gabapentin or Combination of Both in Fibromyalgia Syndrome","status":"UNKNOWN","sponsor":"Mansoura University","isPivotal":false,"enrollment":75,"indication":"Fibromyalgia","completionDate":"2023-11"},{"nctId":"NCT01026077","phase":"N/A","title":"The Savella Pregnancy Registry","status":"TERMINATED","sponsor":"Syneos Health","isPivotal":false,"enrollment":350,"indication":"Fibromyalgia","completionDate":"2024-10-09"},{"nctId":"NCT00757679","phase":"Phase 2","title":"Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran. An Exploratory Placebo-controlled Clinical Trial in Fibromyalgia Out-patients","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","isPivotal":false,"enrollment":153,"indication":"Fibromyalgia Syndrome","completionDate":"2009-09"},{"nctId":"NCT01319825","phase":"Phase 4","title":"Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine.","status":"UNKNOWN","sponsor":"California Medical Clinic for Headache","isPivotal":false,"enrollment":45,"indication":"Migraine With Aura, Migraine Without Aura","completionDate":"2012-07"},{"nctId":"NCT01418651","phase":"Phase 3","title":"Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population: an Open-label Study","status":"TERMINATED","sponsor":"Banner Health","isPivotal":true,"enrollment":20,"indication":"Fibromyalgia","completionDate":"2011-08"},{"nctId":"NCT00793520","phase":"Phase 3","title":"","status":"TERMINATED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":2,"indication":"Fibromyalgia","completionDate":""},{"nctId":"NCT07253207","phase":"Phase 3","title":"A Randomized, Double-Blind, Active-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of Levomilnacipran Hydrochloride Extended-Release Capsules in the Treatment of Pa","status":"COMPLETED","sponsor":"Zhejiang Huahai Pharmaceutical Co., Ltd.","isPivotal":true,"enrollment":392,"indication":"Major Depressive Disorder (MDD)","completionDate":"2025-07-22"},{"nctId":"NCT01329406","phase":"Phase 4","title":"A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis","status":"UNKNOWN","sponsor":"Analgesic Solutions","isPivotal":false,"enrollment":50,"indication":"Osteoarthritis","completionDate":"2012-09"},{"nctId":"NCT02466958","phase":"Phase 4","title":"Double-blind Placebo-controlled Trial of Levomilnacipran in Geriatric Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","isPivotal":false,"enrollment":29,"indication":"Major Depressive Disorder","completionDate":"2018-12-09"},{"nctId":"NCT01207453","phase":"Phase 4","title":"Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","isPivotal":false,"enrollment":49,"indication":"Arthritis, Rheumatoid","completionDate":"2013-11"},{"nctId":"NCT01780389","phase":"Phase 4","title":"Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)","status":"COMPLETED","sponsor":"Duke University","isPivotal":false,"enrollment":5,"indication":"Knee Pain After Total Knee Arthroplasty, Osteoarthritis Pain","completionDate":"2011-07"},{"nctId":"NCT01225068","phase":"Phase 2","title":"An Exploratory Randomized Placebo Controlled Trial of Milnacipran in Patients With Chronic Neuropathic Low Back Pain","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":40,"indication":"Low Back Pain","completionDate":"2012-04"},{"nctId":"NCT00436033","phase":"Phase 3","title":"A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","isPivotal":true,"enrollment":1429,"indication":"Fibromyalgia Syndrome","completionDate":"2007-09"},{"nctId":"NCT01829243","phase":"Phase 3","title":"Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia: A 13-week Randomized, Placebo Controlled Cross Over Trial","status":"COMPLETED","sponsor":"Duke University","isPivotal":true,"enrollment":26,"indication":"Fibromyalgia, Neurocognition","completionDate":"2013-05"},{"nctId":"NCT03249311","phase":"Phase 4","title":"Effectiveness of the Norepinephrine and Serotonin Reuptake Inhibitor Levomilnacipran in Healthy Males","status":"UNKNOWN","sponsor":"University of Ottawa","isPivotal":false,"enrollment":36,"indication":"None (i.e. Healthy Volunteers)","completionDate":"2022-05-01"},{"nctId":"NCT01377194","phase":"Phase 3","title":"A Double-blind, Placebo-Controlled, Fixed-Dose Study of Levomilnacipran SR in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":568,"indication":"Major Depressive Disorder","completionDate":"2012-03"},{"nctId":"NCT03905486","phase":"NA","title":"The Efficacy of Pregabalin as a Monotherapy Versus Combined Pregabalin and Milnacipran in the Management of Fibromyalgia.","status":"COMPLETED","sponsor":"Yousra Hisham Abdel Fattah","isPivotal":false,"enrollment":58,"indication":"Fibromyalgia, Primary","completionDate":"2019-12-31"},{"nctId":"NCT00817375","phase":"NA","title":"Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients","status":"UNKNOWN","sponsor":"Samsung Medical Center","isPivotal":false,"enrollment":1000,"indication":"Depression, Adverse Reaction to Drug","completionDate":"2018-12"},{"nctId":"NCT01173055","phase":"Phase 4","title":"A Randomized, Double-blind,Placebo-controlled, Two-way Crossover Study to Evaluate the Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging Activation Patterns in Patient","status":"COMPLETED","sponsor":"University of Michigan","isPivotal":false,"enrollment":22,"indication":"Fibromyalgia","completionDate":"2012-06"},{"nctId":"NCT02783430","phase":"Phase 2","title":"Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease","status":"COMPLETED","sponsor":"University Hospital, Lille","isPivotal":true,"enrollment":42,"indication":"Depression","completionDate":"2024-03-08"},{"nctId":"NCT00969150","phase":"Phase 3","title":"A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":362,"indication":"Major Depressive Disorder","completionDate":""},{"nctId":"NCT01085812","phase":"Phase 3","title":"A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":734,"indication":"Depression, Major Depressive Disorder","completionDate":"2011-10"},{"nctId":"NCT01288807","phase":"Phase 4","title":"Effects of a 12 Week Milnacipran 200 mg Treatment on Pain Perception and Pain Processing in Fibromyalgia - An Open Label Study","status":"COMPLETED","sponsor":"University of California, San Diego","isPivotal":false,"enrollment":8,"indication":"Fibromyalgia","completionDate":"2015-01"},{"nctId":"NCT03128021","phase":"Phase 4","title":"Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)","status":"COMPLETED","sponsor":"Howard Aizenstein","isPivotal":false,"enrollment":57,"indication":"Major Depressive Disorder","completionDate":"2023-08-30"},{"nctId":"NCT01471379","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Milnacipran in the Treatment of Irritable Bowel Syndrome","status":"TERMINATED","sponsor":"Spencer Dorn, MD, MPH","isPivotal":false,"enrollment":2,"indication":"Irritable Bowel Syndrome","completionDate":"2013-02"},{"nctId":"NCT03797560","phase":"NA","title":"Comparison the Treatment Effects Between Ba-Duan-Jin and Pregabalin in Patients with Fibromyalgia","status":"COMPLETED","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","isPivotal":false,"enrollment":104,"indication":"Fibromyalgia","completionDate":"2022-10-31"},{"nctId":"NCT01352572","phase":"NA","title":"Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients","status":"UNKNOWN","sponsor":"Samsung Medical Center","isPivotal":false,"enrollment":300,"indication":"Depression","completionDate":"2018-12"},{"nctId":"NCT00314249","phase":"Phase 3","title":"A Phase III Pivotal, Multicenter, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":1025,"indication":"Fibromyalgia","completionDate":""},{"nctId":"NCT00969709","phase":"Phase 3","title":"A Double-blind, Placebo-Controlled, Fixed-Dose Study of F2695 SR in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":724,"indication":"Major Depressive Disorder","completionDate":""},{"nctId":"NCT03321526","phase":"Phase 2","title":"A 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":false,"enrollment":107,"indication":"Depressive Disorder, Major","completionDate":"2019-06-27"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}